Why it matters
This adds another concrete therapeutic path inside the federal healthspan portfolio and helps define what kinds of interventions and outcomes PROSPR will test.
Decision implication
Track outcome selection, human trial design, safety, biomarker changes, and whether results support broader healthspan claims.
Who or what is affected
- ARPA-H
- Linnaeus Therapeutics
- researchers
- regulators
- healthspan industry
Evidence and sources
Decision priority: Watch
Source authority: Primary/authoritative · official ARPA-H source
Evidence design: Program record
Applicability: Direct
Confidence for the stated claim: High
Freshness: Current
- https://arpa-h.gov/explore-funding/awards/4196
- https://arpa-h.gov/news-and-events/research-teams-add-more-healthy-years-americans-lives-they-age
P4L distinguishes the sourced record from interpretation. Program inclusion, participation, funding, proposal status, or a public listing does not by itself establish clinical effectiveness, endorsement, coverage, or scaled adoption unless the cited source specifically establishes it.
For this decision
Researchers · Innovators · Funders/investors · Policymakers · Clinicians
What P4L is watching next
- Trial start
- endpoints
- safety
- efficacy
- regulatory engagement.
Related proof records
Record provenance
- Last verified
- 2026-09-03
- Revision state
- Version 1.1 removes unsupported established-safety and cardiometabolic-benefit wording, adds official corroboration, preserves the investigational award boundary, and records the September 3, 2026 re-verification.
- Status
- Program award · investigational testing · aging/healthspan benefit not established
- Freshness
- Current
- Version
- 1.1
- Stable ID
- SIG-2026-020